The WHO Made Two Separate GLP-1 Calls in 2025

Two headlines went around at the end of 2025. One said the WHO had finally backed weight-loss drugs. The other said the WHO had refused to list them for obesity.

If you read both and felt whiplash, that's fair. They can't both be right, and honestly, neither one is quite what happened.

Here's what the headlines flattened. The WHO made two separate moves in 2025, months apart, and they were two different kinds of decision. One was a listing. The other was a clinical recommendation. Squash them into a single yes-or-no and the whole story stops making sense.

So what did the WHO do in 2025?

Two things, on two dates.

In September 2025, the WHO added GLP-1 therapies to its Essential Medicines List — the catalog of drugs it thinks health systems should prioritize stocking. That addition was for managing type 2 diabetes in high-risk groups. Not obesity on its own. Hold onto that detail, because it's where most of the confusion starts.

Then, on 1 December 2025, the agency published its first global guideline on using GLP-1 medicines to treat obesity. That's a different instrument. A listing says a health system should be able to obtain a drug. A guideline tells clinicians how strong the evidence is for actually using it, and for whom.

So one move was about supply and priority. The other was about clinical confidence. Keeping them apart is the whole game.

September: what got listed, and for whom

The wording matters, so here's the listing indication in plain terms:

Used as glucose-lowering therapy for adults with type 2 diabetes who also have established cardiovascular disease or chronic kidney disease and obesity, defined as a body mass index of 30 or higher.

Read that slowly. It isn't a listing for obesity. It's a listing for a specific, high-risk slice of people with type 2 diabetes, and it stacks three conditions on top of each other. You need type 2 diabetes. You need established heart disease or chronic kidney disease. And you need obesity, defined as a BMI of 30 or higher. All three, together. The drugs go on the list as a glucose-lowering therapy for that group, not as a weight tool for the general population.

It helps to know what "essential medicine" even means. The list is a procurement signal. It tells health systems, especially in lower- and middle-income countries, which drugs are worth prioritizing. It's not a personal prescription endorsement, and it's not the same as your country deciding to cover the drug. More on that gap in a minute.

The four drugs that made the list

Four medicines went on, and the WHO is careful about how it labels them. Three are GLP-1 receptor agonists: semaglutide (sold as Ozempic for diabetes and Wegovy for obesity), dulaglutide, and liraglutide. The fourth is tirzepatide (Mounjaro, or Zepbound for obesity), which the agency describes as a GLP-1/GIP dual receptor agonist rather than a pure GLP-1. That last distinction is easy to skim past, but tirzepatide works on two gut-hormone receptors, not one.

The same announcement carried a caveat that tells you where the WHO's head is at:

High prices of medicines like semaglutide and tirzepatide are limiting access to these medicines.

That's the agency naming affordability as the barrier. Not a price tag, a policy statement. Getting a drug onto the essential list is partly a lever to push that price down over time.

December: the first global guideline on obesity

This is the second move, and the one people really mean when they ask whether the WHO "backs" these drugs. On 1 December 2025, the guideline said, in plain terms:

GLP-1 therapies may be used by adults, but excluding pregnant women, for the long-term treatment of obesity.

A few things to notice. It's about obesity now, directly, not diabetes. It's for adults, and it carves out pregnant women. It frames these as long-term treatments, not a short course. And the drug list is a little different: the guideline covers three medicines — liraglutide, semaglutide, and tirzepatide — one fewer than the four on the essential-medicines list, with dulaglutide off the obesity roster.

But the most consequential word in that recommendation isn't a drug name. It's "conditional."

"Conditional" is doing a lot of work here

"Conditional" sounds lukewarm, and plenty of people read it as the WHO hedging on whether the drugs work. That's the wrong reading.

The recommendation is labeled conditional not because the agency doubts these medicines lower weight. It's conditional because of what's still unsettled around them: limited data on long-term efficacy and safety, on what happens with maintenance and discontinuation, on their current costs, on whether health systems are ready to deliver them, and on equity — who gets access and who doesn't.

So the uncertainty is about the world around the drug, not its effect on the scale. That's a different kind of caution than "we're not sure this does anything."

So did the WHO turn down weight-loss drugs? No.

Back to those two headlines. "The WHO backed weight-loss drugs" overstates it, because the obesity recommendation is a conditional yes with a stack of caveats attached. "The WHO refused to list them for obesity" misreads it, because the essential-medicines listing was always a diabetes-context decision, and the agency's actual stance on obesity lives in the December guideline, which is not a no.

The trap is treating "not on the essential list for obesity alone" as a verdict against the drugs. It isn't. It reflects evidence that's still maturing on the questions above, plus the plain fact that the list and the guideline are two tools doing two jobs.

One more misread worth heading off: a WHO listing is an international reference standard. It's not your country's approval, and it's definitely not your insurance formulary. Whether you can get one of these drugs, and whether anyone helps pay for it, comes down to your national regulator and your health plan. Those are separate decisions from anything the WHO published.

The heart-disease trial sitting underneath all this

When policy bodies weigh these drugs, one trial keeps coming up: SELECT. It's worth understanding, because it's easy to quote badly.

In SELECT, a major cardiovascular event occurred in 6.5% of people taking semaglutide, compared with 8.0% of those on placebo. Two ways to say one result. In absolute terms, that's a gap of 1.5 percentage points between the groups. Expressed as relative risk, it's a hazard ratio of 0.80 — roughly a 20% lower risk on the drug. Both numbers describe the same finding; they're just measured on different axes, so don't mash the "1.5 points" and the "20%" together as if they were one figure.

And here's the caveat that matters for this whole story: SELECT enrolled adults who had established heart disease and overweight or obesity but did not have type 2 diabetes. That's a different population from the one the essential-medicines listing describes, which is explicitly people with diabetes. SELECT is background evidence the WHO could weigh. It wasn't one of the 2025 policy actions, and it wasn't the same group of patients.

Access, cost, and what this means where you live

Here's the sober part. Even with production ramping up fast, the WHO projects that GLP-1 therapies will reach fewer than 10% of the people who could benefit by 2030. That's the access reality sitting under the optimistic headlines.

Separately, to show the scale the agency is responding to: obesity affects people in every country and was associated with 3.7 million deaths worldwide in 2024. "Associated with" is the honest phrasing — it's a statistical link across a lot of conditions, not a clean tally of deaths obesity caused. I'm keeping those two figures apart on purpose, because it's tempting to multiply them into a scarier sentence than the data supports.

So what do you do with all this? Mostly, use it as a lens. When your country starts debating coverage or approval for these drugs, you'll recognize which WHO document is being cited and what it actually claims. And if you're wondering whether one of these is right for you, that's a conversation to bring to your own doctor. The WHO's job here is the global standard, not your personal prescription.

Since we're naming drugs, a word on safety

Since the drugs are on the table, it's worth drawing the safety lines cleanly, because they don't all carry the same weight. Take semaglutide's US label as the example:

Those are three different tiers. The medullary thyroid carcinoma and MEN2 history is an outright contraindication, a boxed warning, which is the US FDA's most serious label flag. Acute pancreatitis sits a step below: a warning, where the instruction is to stop and reassess if it's suspected rather than to bar treatment from the start. And the gut stuff is common and usually early, the sort of thing that's managed rather than feared.

Two footnotes here. First, "boxed warning" is US FDA language. Other regulators write their labels differently, and approvals and indications vary market to market, so your local prescriber's guidance is what governs, not a US label. Second, none of these individual signals is why the December guideline is "conditional." That label, remember, is about long-term evidence, cost, and equity, not about any single side effect. Worth keeping straight so the safety picture doesn't read as scarier than it is.

Everything above comes straight from the WHO's own announcements and the published trial behind them. What any of it means for your prescription is a question for you and your doctor, not for a headline that had to choose between "approved" and "refused."

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app